Skip to main content

Day: March 8, 2021

Tillaga fyrir aðalfund Sláturfélags Suðurlands svf. 19. mars 2021

Eftirfarandi tillaga hefur borist stjórn Sláturfélags Suðurlands:Aðalfundur Sláturfélags Suðurlands haldinn á Goðalandi í Fljótshlíð 19. mars 2021, samþykkir að stjórn Sláturfélags Suðurlands láti vinna skýrslu þar sem þróun sölu einstakra kjöttegunda í gegnum vinnslu félagsins verði greind frá árinu 2000.Greinargerð:Í 3 gr. samþykkta félagsins segir: „Tilgangur félagsins er að annast slátrun, úrvinnslu og sölu á framleiðslu félagsmanna.‘‘Í ljósi harðnandi samkeppni á kjötmarkaði og verri afkomu félagsins teljum við sem félagsmenn í þessu samvinnufélagi bænda mikilvægt að kalla eftir þessum upplýsingum svo að staða félagsins í úrvinnslu afurða bænda sé gerð ljósari og eins hvert félagið stefni í sínum rekstri.Ágúst Ingi KetilssonGeir GíslasonReynir Þór JónssonStefán GeirssonTrausti HjálmarssonAðalfundur Sláturfélags Suðurlands verður...

Continue reading

InfuSystem to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 17, 2021

ROCHESTER HILLS, Michigan, March 08, 2021 (GLOBE NEWSWIRE) — InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that it will issue fourth quarter and full year 2020 financial results on Wednesday, March 17, 2021, before the market opens.The Company will also conduct a conference call for all interested investors on Wednesday, March 17, 2021, at 9:00 a.m. Eastern Time to discuss its financial results.To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investors section of the Company’s website at https://ir.infusystem.com/.  A replay of the call will be available...

Continue reading

MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

LA JOLLA, Calif., March 08, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC. The conference will take place on March 17 – 18, 2021 from 9:00 am-5:00 pm EST featuring roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A, and presentations from hundreds of issuers both domestically and internationally.Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will be available for one-on-one meetings and investors...

Continue reading

Radisson appoints Hubert Parent-Bouchard as Chief Financial Officer

ROUYN-NORANDA, Quebec, March 08, 2021 (GLOBE NEWSWIRE) — Radisson Mining Resources Inc. (“Radisson” or the “Company“) (TSX.V: RDS, OTC: RMRDF) is pleased to announce the promotion of Hubert Parent-Bouchard to Chief Financial Officer from Director, Corporate Development effective March 5, 2021.Mr. Parent-Bouchard has more than ten years of finance, accounting and capital markets experience. He has worked in various capacities with increasing responsibilities at Radisson since 2014. Since joining Radisson, he has played an instrumental role in several aspects of the Company, including business restructuring and management, leadership recruitment, accounting, financing, corporate development and investor relations. He was directly involved in the raise of more than $30 M in equity for the growth and the exploration activities of the...

Continue reading

Radisson nomme Hubert Parent-Bouchard comme Chef de la direction financière

ROUYN-NORANDA, Québec, 08 mars 2021 (GLOBE NEWSWIRE) — Rouyn-Noranda, Québec : Ressources minières Radisson Inc. (TSXV: RDS) (« Radisson » ou la « Société ») est heureuse d’annoncer la promotion de Hubert Parent-Bouchard, de Directeur du développement des affaires, à Chef de la direction financière en date du 5 mars 2021.M. Parent-Bouchard possède plus de dix années d’expérience en finance, comptabilité et marché des capitaux. Il a travaillé à diverses capacités avec une augmentation des responsabilités graduelles au sein de Radisson depuis 2014. Depuis avoir joint Radisson, il a joué un rôle clé dans plusieurs aspects de la Société, incluant sa restructuration et sa gestion, le recrutement de leadership, les financements, les initiatives corporatives et les relations aux investisseurs. Il a été impliqué directement dans la levée...

Continue reading

Wallbridge Continues to Report Wide Intersections from Definition Drilling at Fenelon

TORONTO, March 08, 2021 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM) (“Wallbridge” or the “Company”) is pleased to announce new results from its definition drill program at the Fenelon Gold Property (“Fenelon” or the “Property”), with strong gold intersections that continue to confirm the grade and geometry of the central portions of the Tabasco-Cayenne and Area 51 Zones, in support of the maiden mineral resource estimate planned for Q3 2021.Fenelon Gold System, Tabasco-Cayenne Definition Drill ResultsHighlight intersections from the definition drilling in the Tabasco-Cayenne Zones include:“Definition drilling in the central portions of the known Fenelon Gold System (sections 9900E to 10250E) consistently shows good predictability of the zones and provides the tighter spaced information required for the upcoming...

Continue reading

CytoDyn to Release CD12 Trial Detailed Results via Form 8-K After Investment Community Webcast, Monday, March 8

These trial results are currently being prepared to be submitted for publicationVANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it will release the CD12 clinical trial data via a Form 8-K after the investment community webcast on Monday, March 8, 2021. The Company’s recently completed CD12 Phase 3 trial evaluated leronlimab for the treatment of patients with severe-to-critical COVID-19.A summary of the key findings from this CD12 Phase 3 trial with leronlimab as a treatment for severe-to-critically ill COVID-19 patients is as follows:With the age adjustment analysis in all other major secondary...

Continue reading

Zomedica Retires Preferred Shares

ANN ARBOR, Mich., March 08, 2021 (GLOBE NEWSWIRE) — Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has effected the exchange of all of its outstanding Series 1 Preferred Shares for its common shares and that it continues to progress with its planned commercialization of its TRUFORMA® platform.Effective March 7, 2021, Zomedica completed the exchange of all 12 of its outstanding Series 1 Preferred Shares, stated value $1.0 million per share, (the “Preferred Shares”) for 24,719,101 common shares of the Company, equivalent to $44 million based on a $1.78 per share closing price of the common shares on March 5, 2021. Robert Cohen, Chief Executive Officer of Zomedica, commented: “As you know, since our...

Continue reading

Canadian Credit Market Poised for Growth

Canadian credit consumers show continued perservance, aided by government subsidies and payment deferralsQ4 2020 credit activity was strong, driven by growth in auto and mortgage lendingOverall delinquency levels remain very low; credit card delinquencies edged up slightly but do not show cause for concernTORONTO, March 08, 2021 (GLOBE NEWSWIRE) — TransUnion today released the findings of its Q4 2020 TransUnion Industry Insights Report, which observed an increase in consumer credit activity. This increase appears driven in part by recent improvements in economic and labor market activity, as well as government relief measures and payment deferral programs supported by lenders. Consumer credit activity picked up in the final quarter of 2020, and while generally still below the prior year balance and origination levels, particularly...

Continue reading

AppTech and NEC Payments Announce Financial Close of their Agreement

CARLSBAD, Calif. and MANAMA, Kingdom of Bahrain, March 08, 2021 (GLOBE NEWSWIRE) — AppTech Corp. (“AppTech”) (OTC: APCX) and NEC Payments B.S.C(c) (“NECP”) today announce financial closure of the agreement entered into by the parties in October 2020.Under the scope of the agreement, NECP will provide a digital banking and payment technology solution that will enable AppTech to extend its product offering to include flexible, scalable, and secure payment acceptance and issuer payment processing. Through the deployment of NECP’s technologies, AppTech will be empowered to drive the digitization of business and consumer payments flows and migrate cash, along with other legacy payment types to distanced, contactless card, and real-time payment transactions.Additionally, NECP will assist AppTech by providing best in class software to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.